Opdivo Combination Therapy Shows Survival Benefit in Metastatic Urothelial Carcinoma

Bristol Myers Squibb has announced positive results from the Phase 3 CheckMate -901 trial, showing that the combination of Opdivo (nivolumab) with cisplatin-based chemotherapy followed by Opdivo monotherapy demonstrated significant benefits in overall survival (OS) and progression-free survival (PFS) compared to standard-of-care cisplatin-based combinations as a first-line treatment for patients with unresectable or metastatic urothelial carcinoma who are eligible for cisplatin-based chemotherapy. This marks the first immunotherapy-based combination to improve both OS and PFS in this patient population, highlighting the potential of Opdivo-based treatments in various genitourinary cancers.